MedTrace Logo

Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology

NCT04296201 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-02-17

No results posted yet for this study

Summary

A total of at least 15 and up to 17 healthy subjects at a single site, aged 25-45 years old, who wish to receive a lifting effect and improved muscle definition, will be included in the study.

The procedure will include treatments with the Legend Pro™ DMA™ technology. Photos will be obtained at pre-defined time points throughout the study.

Conditions

  • Skin Laxity
  • Muscle Contracture

Interventions

DEVICE

DMA treatment

Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.

Sponsors & Collaborators

  • Lumenis Be Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-02-15
Completion
2021-02-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04296201 on ClinicalTrials.gov